SUMMARY
# Ferroptosis Validation in Parkinson's Disease
## Background and Rationale
This clinical validation study investigates ferroptosis as a therapeutic target in Parkinson's disease (PD), building on emerging evidence that iron-dependent lipid peroxidation contributes significantly to dopaminergic neurodegeneration. Ferroptosis, a distinct form of regulated cell death characterized by iron accumulation and lipid peroxidation, has been implicated in PD pathogenesis through multiple mechanisms includ
METHODOLOGY NOTES
**Phase 1: In Vitro Model Development (Months 1-12)**
• Establish primary dopaminergic neuronal cultures from human iPSCs differentiated using FOXA2/LMX1A protocol
• Generate isogenic PD patient-derived iPSC lines with SNCA, LRRK2, and PRKN mutations (n=30 lines per mutation)
• Develop ferroptosis induction protocols using erastin (10-20 μM), RSL3 (1-5 μM), and FIN56 (2-10 μM)
• Validate ferroptosis markers: lipid peroxidation (C11-BODIPY), iron accumulation (calcein-AM quenching), GPX4 depletion
• Screen ferroptosis inhibitors: ferrostatin-1 (1-10 μM), liproxstatin-1 (1-5 μM), vitamin E (50-200 μM)
• Measure ATP production, mitochondrial membrane potential, and ROS levels using fluorometric assays
**Phase 2: Biomarker Validation (Months 13-24)**
• Recruit early-stage PD patients (n=150, Hoehn-Yahr Stage 1-2, UPDRS-III 10-40)
• Recruit age-matched healthy controls (n=75)
• Collect cerebrospinal fluid via lumbar puncture and plasma samples
• Quantify ferroptosis biomarkers: 4-hydroxy